Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis
Clinical Pharmacology & Therapeutics · 2026-07 · 120 (1) · 109-113
DOI: 10.1002/cpt.70256 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 05.03.2026. Verfasst von Antonio Tursi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Territorial Gastroenterology Service, Barletta-Andria-Trani (BAT) Local Health Agency, Andria, Italy. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Mesalamine, Janus Kinase Inhibitors, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib ( n = 181), upadacitinib ( n = 313), or filgotinib ( n = 139) were included. Time to clinical remission was analyzed using interval‐censored Cox models. Among the 633 patients treated with JAKi, 476 patients received 5‐ASA, and 151 did not. Cumulative probability of remission at week 48 was similar with and without 5‐ASA, at 81.3% and 77.0%, respectively. The adjusted hazard ratio for 5‐ASA vs. no 5‐ASA was 1.12 (95% CI 0.91–1.37, P = 0.519). We therefore found that concomitant 5‐ASA did not significantly affect the time to clinical remission in UC patients treated with JAKi.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Territorial Gastroenterology Service, Barletta-Andria-Trani (BAT) Local Health Agency, Andria, Italy.
- Department of Translational Medicine and Surgery, School of Medicine, Catholic University, Rome, Italy.
- Division of Gastroenterology, Azienda Ospedale-Università "San Martino", University of Genoa, Genoa, Italy.
- Division of Gastroenterology, A.O. "S. Camillo-Forlanini" Hospital, Rome, Italy.
- Gastroenterology Unit, Azienda Ospedale-Università di Padova (AOUP), Padua, Italy.
- Division of Gastroenterology, AORN "Brotzu" Hospital, Cagliari, Italy.
ORCID-Profile: Antonio Tursi, Andrea Pasta, Walter Elisei, Brigida Barberio, Giammarco Mocci, Giovanni Maconi, Antonietta Gerarda Gravina, Raffaele Pellegrino, Giorgia Bodini, Edoardo Vincenzo Savarino, Alfredo Papa
Zitieren
APA
Tursi, A., Pasta, A., Elisei, W., Barberio, B., Mocci, G., Maconi, G., Gravina, A. G., Pellegrino, R., Bodini, G., Savarino, E. V., Papa, A., & Italian Network for Inflammatory Bowel Diseases (IN‐IBD) (2026). Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis. Clinical Pharmacology & Therapeutics, 120(1), 109-113. https://doi.org/10.1002/cpt.70256
Vancouver
Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Maconi G, et al. Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis. Clinical Pharmacology & Therapeutics. 2026;120(1):109-113. doi:10.1002/cpt.70256
BibTeX
@article{Tursi2026,
author = {Tursi, Antonio and Pasta, Andrea and Elisei, Walter and Barberio, Brigida and Mocci, Giammarco and Maconi, Giovanni and Gravina, Antonietta Gerarda and Pellegrino, Raffaele and Bodini, Giorgia and Savarino, Edoardo Vincenzo and Papa, Alfredo and Italian Network for Inflammatory Bowel Diseases (IN‐IBD), Italian Network for Inflammatory Bowel Diseases (IN‐IBD)},
title = {Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {120},
number = {1},
pages = {109--113},
doi = {10.1002/cpt.70256}
}
EUVIMED